Navigation Links
Regenesis Biomedical Announces Additions to Board of Directors
Date:8/22/2008

Strengthens breadth of experience and business expertise

SCOTTSDALE, Ariz., Aug. 22 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical technology company that markets the Provant(R) Wound Therapy System, announced today the addition of two members to its Board of Directors. The two new directors are Peter G. Savas, Chairman and CEO of Alseres Pharmaceuticals, and Charles "Chuck" S. Lunden, a principal with Bederson and Company.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080422/LATU008)

Peter Savas serves as Chairman and Chief Executive Officer of Alseres Pharmaceuticals. Prior to joining Alseres, Peter was Chairman and Chief Executive Officer of Aderis Pharmaceuticals, where he completed a $45 million private placement, strengthened the Board of Directors, Scientific Advisory Board and management team and rationalized the company's new product development partnerships. Peter holds his Bachelor of Arts degree in chemistry from Syracuse University.

Chuck Lunden is a Principal with Bederson and Company, certified public accountant consultants who provide financial and accounting services. He has comprehensive experience in corporate valuation and financial, tax and corporate management services. His designations include Certified Public Accountant, Accredited in Business Valuations, Certified Fraud Examiner, Certified Management Accountant, Chartered Life Underwriter, and Fellow of the Life Management Institute. Chuck holds a Bachelor of Science degree in economics from the University of Pennsylvania's Wharton School of Business. He is a member of the Board of Directors of HealthCare Data Diagnostics, a Medicare data analysis firm specializing in fraud detection. He is also a Member of the Board of Directors of the Spanish Health Ministries Inc.

"We are pleased to welcome these outstanding individuals to our team," said Virginia Rybski, Acting President of Regenesis. "Regenesis continues to demonstrate impressive revenue growth, and the perspectives of these individuals will contribute to our ongoing business plan execution."

About the Provant Wound Therapy System

Provant uses pulsed-radio frequency energy (PRFE) to facilitate reduction of the pain and edema associated with post-operative superficial soft tissues.

About Regenesis Biomedical

Regenesis Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. Regenesis developed, patented, and now markets the Provant Wound Therapy System. Our customers include health care facilities, acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and wound care clinics.

Contact: Regenesis Biomedical, Inc.

Scott Robey, Vice President Marketing

http://www.regenesisbiomedical.com 480-970-4970


'/>"/>
SOURCE Regenesis Biomedical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medicare Exemplary Provider Accreditation Awarded to Regenesis Biomedical
2. Regenesis Biomedical Appoints Scientific Advisory Board Composed of Life Science and Electronics Experts
3. Advanced BioHealing and Regenesis Biomedical Form Co-Promotion Alliance for Dermagraft(R)
4. Regenesis Biomedical Advances Corporate Strategy by Appointing Vice President of Marketing
5. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
6. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target
7. ArunA Biomedical Names William T. Sharp President and Chief Executive Officer
8. Roche and Response Biomedical Corporation Aim to Reduce Vein-to-Brain Time with New Point-of-Care Cardiac Tests
9. Frontage Laboratories Completes Acquisition of Advanced Biomedical Research, Inc. (ABR)
10. HIPAA Privacy Rule Impedes Biomedical Research
11. Ten Latin American Scientists Named 2008 Pew Fellows in the Biomedical Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... -- With the growing need for better therapeutics, and ... such as monoclonal antibodies, recombinant protein therapeutics and ... are in high demand. Conventionally expression systems were ... of these therapeutics. However, due to issues with ... approaches and novel expression systems are currently being ...
(Date:2/3/2016)... , ... February 03, 2016 , ... ... established a new office dedicated to the North American healthcare market. , Aerocom ... to healthcare facilities. The company will provide new pneumatic tube systems or ...
(Date:2/3/2016)... -- Silk Therapeutics, Inc., today announced the closing of a $6 ... a total of $10.25 million in Series A funding based ... round was led by existing investor The Kraft Group of ... investors Lear Corporation and Highland Consumer Partners, as well as ... Richard Sackler , MD, with Summer Road, LLC; Erin ...
(Date:2/3/2016)... YORK. (PRWEB) , ... February 03, 2016 , ... ... of silicon (Si) and InGaAs chips and wafers, and InP epi wafers based ... ranging from silicon detectors–including photodiodes, photo transistors, and Avalanche photodiodes–to Si and InGaAs ...
Breaking Biology Technology:
(Date:2/2/2016)... Feb. 2, 2016 This BCC Research ... market by reviewing the recent advances in high ... drive the field forward. Includes forecast through 2019. ... the challenges and opportunities that exist in the ... solution developers, as well as IT and bioinformatics ...
(Date:2/1/2016)... February 1, 2016 Rising sales ... drive global touchfree intuitive gesture control market ... Rising sales of consumer electronics coupled with new technological ... size through 2020   ... with new technological advancements to drive global touchfree intuitive ...
(Date:1/25/2016)... Jan. 25, 2016   Unisys Corporation (NYSE: UIS ... F. Kennedy (JFK) International Airport, New York City ... identify imposters attempting to enter the United States ... them. pilot testing of the system at Dulles ... terminals at JFK during January 2016. --> pilot testing ...
Breaking Biology News(10 mins):